Indel Therapeutics - discovering new drugs against infectious diseases

Management Team

  Malcolm Kendall, MBA    Chief Executive Officer and Director

Mr. Kendall has over 25 years of operational management, entrepreneurial, venture capital investment and leadership experience, the majority of which has been focused on company creation and building value in technology and biotechnology companies. Formerly a life science venture capitalist with MDS Capital and Intersouth Partners, he lectures at the Segal Graduate School of business, Simon Fraser University.

  Neil Reiner, MD                  Chief Scientific Officer, Chairman of the  dddddddddddddddddd       Scientific Advisory Board and Director

Dr. Reiner is an internationally recognized authority on host-pathogen interactions. He is a Professor and Research Director of the Division of Infectious Diseases in the Department of Medicine at the University of British Columbia and Vancouver General Hospital, where he was formerly the Head of the Division of Infectious Diseases. In addition, Dr. Reiner also serves as Director of the Immunity and Infection Research Centre of the Vancouver Coastal Health Research Institute.

  Roger Léger, PhD             Consulting VP of Research

Dr. Léger has more than 16 years of R&D experience, and for over a decade, he has focused on the discovery and development of novel antibiotics. Prior to joining Indel, he was VP of Research at Ulysses Pharmaceuticals, a company focused on discovering and developing novel antibiotics. Prior to this, Dr. Léger was the Director of Medicinal Chemistry at ConjuChem Biotechnologies and a Research Fellow at Microcide Pharmaceuticals, where he was involved in the early discovery of antibacterial natural products and bacterial efflux pump inhibitors.

  Roya Zoraghi, PhD           Director Preclinical Screening

Dr. Zoraghi established and directs Indel’s laboratory and screening activity. She previously headed the MRSA/Chlamydia lab at the Genome Canada PREPARE Project (Proteomics for Emerging Pathogen Response), a large-scale proteomic-based research effort to identify novel drug targets by characterizing protein interaction networks in emerging pathogens.

About Us
Management Team
Board of Directors
Scientific Advisory Board
Market Opportunity
All rights Reserved. © 2011 Indel Therapeutics   |  Disclaimer 604.551.8464